Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.39
- Piotroski Score 3.00
- Grade Outperform
- Symbol (LIAN)
- Company LianBio
- Price $0.32
- Changes Percentage (0%)
- Change -$0
- Day Low $0.31
- Day High $0.32
- Year High $4.99
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
- Last Earnings 02/13/2024
- Ex-Dividend for 5/16 Dividend 03/15/2024
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 03/24/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.82
- Trailing P/E Ratio -0.39
- Forward P/E Ratio -0.39
- P/E Growth -0.39
- Net Income $-110,290,000
Income Statement
Quarterly
Annual
Latest News of LIAN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Alliance vs. Isolation: Harris and Trump's Competing Views on Foreign Policy
Hosted by Sabrina Tavernise, 'The Daily' podcast features Peter Baker and is produced by Nina Feldman, Mary Wilson, Rachelle Bonja, and Carlos Prieto. The show covers American foreign policy, with ins...
By The New York Times | 17 hours ago -
Sun Life Financial (TSX:SLF) Announces Leadership Changes to Drive Growth and Enhance Strategic Alliances
Sun Life Financial is experiencing growth and challenges, with a focus on Asian markets and health solutions. Strong financial health, growth in Asia, and asset management success are highlights. Chal...
By Yahoo! Finance | 19 hours ago -
Cycling star Pogačar wins men's road race at world championships with brilliant solo attack
Tadej Pogačar showcased his dominance in cycling by winning the men's road race at the world championships with a powerful solo attack....
By AP NEWS | 1 day ago
